Alpha-Synuclein Aggregation Cascade
Alpha-synuclein misfolding and aggregation into Lewy bodies is the pathological hallmark of Parkinson's disease and related synucleinopathies. A prion-like spread mechanism is now established.
Overview
Alpha-synuclein is a 140-amino acid protein abundant at presynaptic terminals, involved in vesicle trafficking and neurotransmitter release. Under pathological conditions, α-synuclein misfolds from its native unstructured state into β-sheet-rich oligomers and fibrils. These aggregate into Lewy bodies and Lewy neurites. Crucially, pathological α-synuclein spreads cell-to-cell in a prion-like manner, following predictable anatomical patterns (Braak staging).
Key Steps
- Native α-synuclein (unstructured monomer) exists in equilibrium with membrane-bound α-helical tetramer
- Stress factors (oxidation, phosphorylation, SNCA mutations/duplications) shift equilibrium toward misfolding
- Oligomeric intermediates form — these are the most neurotoxic species
- Oligomers seed fibrillization, forming amyloid-like β-sheet fibrils
- Fibrils accumulate in Lewy bodies; cell-to-cell transmission via exosomes, tunneling nanotubes, or direct secretion
- Receiving neurons take up seeds, templating misfolding of endogenous α-synuclein (prion-like propagation)
Disease Relevance
- Parkinson's: SNCA gene mutations (A53T, A30P, E46K) and multiplications cause familial PD. Sporadic PD involves same aggregation pathway. Anti-α-synuclein immunotherapy (prasinezumab, cinpanemab) is in clinical trials.
Therapeutic Targets
- EGCG: Redirects α-synuclein aggregation toward non-toxic amorphous aggregates
- Curcumin: Inhibits α-synuclein oligomerization and fibril formation in vitro
- NAD+: SIRT1-mediated deacetylation reduces α-synuclein aggregation propensity
- Rapamycin: Autophagy induction promotes α-synuclein aggregate clearance